|
Abstract Objective: To investigate the efficacy of magnesium sulfate injection combined with low molecular weight heparin sodium for treating women with severe preeclampsia, and its effects on the levels of coagulation protein (GSN) and free vitamin D binding protein (VDBP), coagulation function, and pregnancy outcomes. Methods: 82 women with severe preeclampsia were randomly divided into two groups (41 cases in each group). The women in the control group were given magnesium sulfate antispasmodic treatment, while women in the observation group were given magnesium sulfate combined with low molecular weight heparin sodium. The curative effect, complication, pregnancy outcomes, and the changes of serum GSN and VDBP levels before and after treatment of all included women were observed. Results: After treatment, the values of SBP and DBP, FIB level, and 24-hour urinary protein of women in the observation group were 120.35±4.62 mmHg, 92.31±5.14 mmHg, 2.79±1.24 g/L, and 0.29±0.02 g, which were significant lower than those (140.23±5.32 mmHg, 105.32±5.15 mmHg, 3.35±1.16 g/L, and 1.42±0.12 g) of women in the control group (P<0.05). The levels of plasma GSN, VDBP, PT, and AP of women in the observation group were 263.51±69.57μg/ml, 183.69±53.29μg/ml, 15.12±3.15s, and 37.04±8.09 s, which were significant higher than those (183.59±45.87 μg/ml, 136.25±39.54μg/ml, 12.45±2.16s, and 29.15±6.27s) of women in the control group (P<0.05). The incidences of eclampsia, placental abruption, fetal growth restriction, cesarean section, and postpartum hemorrhage of women in the observation group were 0.0%, 2.4%, 0.0%, 53.7%, and 2.4%, which were significant lower than those (14.6%, 14.6%, 9.8%, 85.4%, and 17.1%) of women in the control group (P<0.05). Conclusion: Magnesium sulfate injection combined with low molecular weight heparin sodium for treating women with severe preeclampsia can significantly reduce blood pressure, urinary protein and blood viscosity, decrease plasma GSN and VDBP levels, and improve pregnancy outcomes.
|
